brilliant blue g
Trade name: Coomassie Brilliant Blue
Approved
Dec 20, 2019
Brilliant Blue G is triphenylmethane dye that was developed for use in the textile industry but is now commonly used for staining proteins in analytical biochemistry. The Bradford assay is a standard, rapid dye-binding assay that uses Brilliant Blue G to quantify the amount of protein in a solution. Brilliant Blue G also acts as a selective inhibitor of the P2X purinoceptor channel P2X7 (IC50s = 10.1 and 265 nM for rat and human P2X7, respectively). In mice, it inhibits interleukin-1β expression and reduces neurological injury secondary to traumatic brain injury. Brilliant Blue G was used to prepare the protein reagent for the determination of protein content of the collagenase enzyme isolated from fish waste. It may be employed as a stain for the internal limiting membrane (ILM) for the macular hole (MH) and epiretinal membrane (ERM) surgery. — NCATS
Clinical trial activity
2 trials · 2 clinical orgs · 2 marketing orgs
Earliest trial started Oct 31, 2012 (NCT01627977)
Timeline
1890s
- Jun 1, 1896
Imperial Chemical Industries — First NDA Organization
- Jun 1, 1896
Imperial Chemical Industries — NDA Organization
2010s
- Jan 1, 2012
Earliest Phase 3 Sponsor(trial)
- Jul 31, 2012
Orphan Drug Designation
- Dec 20, 2019
Earliest FDA Approval
- Dec 20, 2019
Dutch Ophthalmic Research Center — Marketing Organization
- Dec 20, 2019
Dutch Ophthalmic Research Center — NDA Secondary Org
Indications
Approved for
Mechanism of action
- P2X2/P2X3 receptorANTAGONIST
P2X2/P2X3 receptor antagonist
- Unspecified targetOTHER
Membrane staining aid in ophthalmic surgery
Aid in ophthalmic surgery. Selectively stains the internal limiting membrane (ILM) but not the epiretinal membrane nor the retina, making it easier to visualize the membrane for removal.
Approval history
- approvedPriority reviewDec 20, 2019
Chemistry & pharmacology
SMILES
[Na+].CCOC1=CC=C(NC2=CC=C(C=C2)C(C3=CC=C(C=C3C)N(CC)CC4=CC=CC(=C4)S([O-])(=O)=O)=C5C=CC(C=C5C)=[N+](CC)CC6=CC=CC(=C6)S([O-])(=O)=O)C=C1- Mol. weight
- 854.02 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
Yes
Sources
- WikipediaCoomassie Brilliant Blue ↗
- NCATSM1ZRX790SI ↗
- ChEMBLCHEMBL4173394 ↗
Also known as
- acid blue 90
- brilliant blue g
- brilliant blue g
- brilliant blue g
- c.i. 42655
- coomassie blue g
- coomassie brilliant blue
- coomassie brilliant blue g250
- coomassie brilliant blue g 250
- serva blue g
- supranol cyanine g
- xylene brilliant cyanine g
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01820520 | Phase 3 | Jan 1, 2013 | Asociación para Evitar la Ceguera en México |
| NCT01627977 | Phase 3 | Oct 31, 2012 | Federal University of Sao Paulo |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Asociación para Evitar la Ceguera en México | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Federal University of Sao Paulo | Academic/Hospital | 1 | 1 | 1 | 2012 |
Marketing (4)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Dutch Ophthalmic Research Center | For profit | MKTG | Dec 20, 2019 |
| Dutch Ophthalmic Research Center | For profit | SYN | Dec 20, 2019 |
| Dutch Ophthalmic Research Center | For profit | NDA2 | Dec 20, 2019 |
| Imperial Chemical Industries | For profit | NDA | Jun 1, 1896 |